Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

May 30, 2019 by Alan Khadavi

Benralizumab (Fasenra) in asthma

Benralizumab (Fasenra) is an interleukin (IL)-5 receptor monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils in the circulation. Benaralizumab is approved for use in Canada, Europe, Japan and the U.S. In the United States, it is indicated for the add-on treatment of patients with asthma aged 12 and up with an eosinophilic phenotype.  Many insurance companies require the eosinophil count to be 150 and up for it to be approved.  Benralizumab has been shown to reduce asthma exacerbations, improve lung function and asthma symptoms.

A recent study published in the Annals of Allergy Asthma and Immunology, titled “Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma”, sought to determine benralizumab’s onset of action and efficacy in morning peak expiratory flow (PEF).

The main conclusions of the study showed that benralizumab produced numerical differences in peak expiratory flow from placebo beginning by day 2 after the first dose, with meaningful improvements observed within 3 weeks for patients with severe uncontrolled asthma.

Benralizumab is initially given every 4 weeks for the first 3 doses, and then it is given every 8 weeks.  Based on this study, patients should expect to see improvement after even the first dose.  There are currently 5 asthma biologic medications on the market. Xolair which was the first one approved, is indicated for allergic asthma. The others are:

New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma

Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil)

Dupilumab for Asthma, a New Indication

It can be difficult to determine which asthma medication is best for which patient.  There are very limited head to head studies, also the costs of them are very high.

Nucala vs. Fasenra vs. Cinqair; A Comparison Study

Nucala (mepolizumab) vs. Cinqair (reslizumab)

Costs of Asthma Biologic Medications

There will be more asthma biologics coming out in the near future too.  It will be important to tailor which medication is right for which asthmatic patient.  Unfortunately for some of these medications, there are biomarkers that are not commercially available to measure.  For instance, Dupixent targets IL 4 & IL 13, but there no commercial labs which test for levels of it.

Allergy Biologics, Past, Present and Future…

More studies and more medications will come out that will help patients and doctors pick the right and best asthma medication.

 

Filed Under: Asthma, biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 16, 2021

Singulair psychiatric side effects; a large study

Singulair psychiatric side effects

January 11, 2021

Allegra during Pregnancy, is it safe?

allegra during pregnancy

December 25, 2020

Moderna Covid Vaccine and Allergy

moderna covid vaccine and allergy

December 12, 2020

Pfizer Covid Vaccine and Allergy

covid vaccine and allergy

December 3, 2020

Budesonide Oral Suspension for Eosinophilic Esophagitis

budesonide oral suspension

December 1, 2020

Indacaterol for severe asthma

indacaterol

November 3, 2020

New treatments for chronic hives

New treatments for chronic hives

October 29, 2020

Xolair for Allergic Rhinitis-A recent study

xolair for allergic rhinitis

October 26, 2020

Semen allergy an overview and treatment

semen allergy

October 21, 2020

Peanut Patch (Viaskin) for peanut allergy

viaskin peanut patch

Read More Posts...

Follow Us…

© 2021 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page